Romark Laboratories, L.C. Romark Laboratories, L.C. Romark Laboratories, L.C. Romark Laboratories, L.C. Romark Laboratories, L.C.

News & Events


Results of US Clinical Trial Published in The Lancet Infectious Diseases

Trial Successfully Achieves Primary Efficacy Endpoint, Reducing Duration of Symptoms of Acute Uncomplicated Influenza

50 Specialty Territory Managers Across the U.S. to Promote the Company’s Products to Gastroenterologists and Primary Care Physicians

Proceeds Used to Establish and Expand Manufacturing Capacity for the Company’s Products

Proceeds of Senior Secured Notes Provide Capital for Expansion of Commercial Organization

Lupin Acquires Exclusive License to Promote and Distribute Alinia® for Oral Suspension in the United States using its Pediatric-Focused Sales Force

$44 Million Contract with U.S. Department of Health and Human Services to Fund Completion of Clinical Development and Preparation for Submission of New Drug Application for NT-300

Romark Laboratories announced results from its STEALTH C-3 clinical trial, a phase 2 clinical study of nitazoxanide in treatment-naïve patients with genotype 1 chronic hepatitis C. Study results were presented as a late breaking communication at the International Liver CongressTM 2010, the 45th Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria.